After an unusual review rejection, the FDA reverses course—a regulatory whiplash that could raise concerns about regulatory consistency.

The FDA denied an application for its flu vaccine, deepening regulatory doubt and complicating forecasts for vaccine-driven revenue growth.

The news: HHS Secretary Robert F. Kennedy Jr. canceled $500 million in federal mRNA grants, eliminating flu, COVID-19, and infectious disease research that used the technology. The Biomedical Advanced Research and Development Authority (BARDA) agency nixed 22 contracts, including ones with Moderna, Pfizer, and AstraZeneca.

The news: BioNTech is buying cancer vaccine researcher and one-time COVID-19 vaccine rival CureVac in a $1.25 billion all-stock deal. The takeaway: The new HHS is taking a less-than-positive view on mainstream vaccines and mRNA technology, but it’s also signaled strong interest in personalized medicines and novel therapies. That’s good news for BioNTech, and could be a sign to other pharmas and biotechs that precision and specialty drugs are poised for fast tracking, while vaccines caught up in public and political controversy will be overscrutinized and delayed to market.

The news: Moderna has agreed to conduct a true placebo-controlled trial of its new COVID-19 vaccine, according to a post on X this week from Robert F. Kennedy, Jr. Our take: It’s difficult for vaccine makers to keep up with shifting requirements for getting shots approved, and for which groups of people. Companies may soon have to weigh pouring billions more into vaccine R&D against expanding or growing product offerings to other drug markets.

GenAI is changing pharma marketing from content creation to pharmacovigilance. Brand marketers and agencies are moving from experimentation to broad adoption of AI assistance and more efficient, effective, and relevant consumer communications.

Trump administration drops Moderna mRNA pandemic flu research: This adds to increasing doubt around the validity of mRNA vaccines, and will likely cause uncertainty for drugmakers looking to federal agencies for vaccine guidance.

FDA’s approval process for new COVID-19 vaccines will soon get tougher: But the impact to leading vaccine makers like Pfizer and Moderna might be minimal. Here’s why.

Trump taps RFK Jr. to lead Health and Human Services: If confirmed, the vaccine skeptic’s appointment would hold serious implications for Big Pharma.